argenx SE - American Depositary Shares (NQ:ARGX)

916.93 -2.28 (-0.25%)

Delayed Quote Updated: 9:30 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx ↗

March 22, 2022

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical...

Via Benzinga

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder ↗

March 22, 2022

Argenx SE (NASDAQ: ARGX) ) has

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗

March 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: argenx Q4 Earnings ↗

March 03, 2022

argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx...

Via Benzinga

argenx's Earnings: A Preview ↗

March 02, 2022

argenx (NASDAQ:ARGX) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

What 8 Analyst Ratings Have To Say About argenx ↗

January 18, 2022

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) withi...

Via Benzinga

argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

March 22, 2022

From argenx SE

Via Business Wire

What 8 Analyst Ratings Have To Say About argenx ↗

March 07, 2022

argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 4...

Via Benzinga

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗

January 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...

Via Benzinga

argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis

January 20, 2022

From argenx

Via Business Wire

What 8 Analyst Ratings Have To Say About argenx ↗

December 21, 2021

Within the last quarter, argenx (NASDAQ:ARGX) has observed the following an...

Via Benzinga

Analyst Ratings For argenx ↗

December 08, 2021

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) withi...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

argenx Highlights Strategic Priorities for 2022

January 07, 2022

From argenx

Via Business Wire

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

38 Stocks Moving In Monday's Mid-Day Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF...

Via Benzinga

Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease ↗

December 20, 2021

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in adult patients who are anti-...

Via Benzinga

A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 4% ↗

December 20, 2021

Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Federal Reserve, last week...

Via Benzinga

5 Stocks To Watch For December 20, 2021 ↗

December 20, 2021

Some of the stocks that may grab investor focus today are: Wall Street expects Carnival Corporation (NYSE: CCL) to report a quarterly loss at $1.27 per share on revenue of $1....

Via Benzinga

The Week Ahead In Biotech (Dec. 19-25): Key Events Of Holiday-Shortened Week ↗

December 19, 2021

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some...

Via Talk Markets

The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week ↗

December 19, 2021

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also...

Via Benzinga

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

December 17, 2021

From argenx SE

Via Business Wire

The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx ↗

December 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...

Via Benzinga

2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 ↗

December 14, 2021

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...

Via Benzinga

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗

December 08, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

What 4 Analyst Ratings Have To Say About argenx ↗

November 29, 2021

Over the past 3 months, 4 analysts have published their opinion on argenx (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 ↗

November 29, 2021

Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.